- South Korea
- /
- Biotech
- /
- KOSDAQ:A298380
KRX Growth Companies With High Insider Ownership Growing Earnings Up To 99%
Reviewed by Simply Wall St
The South Korean market has recently been in the spotlight due to cultural achievements, such as Han Kang's Nobel Prize win, which underscores the nation's growing influence on the global stage. In this thriving environment, growth companies with high insider ownership are particularly appealing as they often signal strong confidence from those who know the business best and can lead to substantial earnings growth.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.8% | 49.1% |
Bioneer (KOSDAQ:A064550) | 15.8% | 97.6% |
Oscotec (KOSDAQ:A039200) | 26.1% | 122% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 105.8% |
Park Systems (KOSDAQ:A140860) | 33% | 34.6% |
Vuno (KOSDAQ:A338220) | 19.4% | 110.9% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Techwing (KOSDAQ:A089030) | 18.7% | 83.6% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 96.7% |
Let's uncover some gems from our specialized screener.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.11 trillion.
Operations: The company's revenue primarily stems from its biotechnology segment, which generated ₩90.79 billion.
Insider Ownership: 26.6%
Earnings Growth Forecast: 99.5% p.a.
ALTEOGEN is forecast to achieve significant growth, with expected annual revenue increases of 64.2%, outpacing the KR market's 10.4%. Profitability is anticipated within three years, marking above-average market growth. The company's Return on Equity is projected to be very high at 66.3% in three years. Despite trading at 71% below its estimated fair value, shareholders have faced dilution over the past year, and there has been no substantial insider trading activity recently.
- Dive into the specifics of ALTEOGEN here with our thorough growth forecast report.
- According our valuation report, there's an indication that ALTEOGEN's share price might be on the expensive side.
ABL Bio (KOSDAQ:A298380)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ABL Bio Inc. is a biotech research company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.99 trillion.
Operations: The company's revenue segment is primarily derived from biotechnology startups, amounting to ₩32.95 billion.
Insider Ownership: 30.5%
Earnings Growth Forecast: 48.2% p.a.
ABL Bio is positioned for robust growth, with revenue projected to increase by 24.7% annually, surpassing the South Korean market's average. The company is expected to achieve profitability within three years, indicating above-average market growth potential. However, its Return on Equity is forecasted to be relatively low at 13% in three years. Despite recent share price volatility and no significant insider trading activity reported in the past three months, ABL Bio remains a key contender in its sector.
- Take a closer look at ABL Bio's potential here in our earnings growth report.
- The analysis detailed in our ABL Bio valuation report hints at an inflated share price compared to its estimated value.
HYBE (KOSE:A352820)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management, with a market cap of approximately ₩7.68 trillion.
Operations: The company's revenue is derived from three main segments: Label (₩1.28 trillion), Platform (₩361.12 billion), and Solution (₩1.24 trillion).
Insider Ownership: 32.5%
Earnings Growth Forecast: 42.6% p.a.
HYBE demonstrates strong growth potential with earnings expected to grow significantly at 42.6% annually, outpacing the South Korean market average. Despite recent one-off items affecting financial results, the company is trading below its estimated fair value by 22%. HYBE completed a share buyback program for KRW 26.09 billion to stabilize stock prices. However, recent earnings showed a decline in net income and basic earnings per share compared to last year’s figures.
- Unlock comprehensive insights into our analysis of HYBE stock in this growth report.
- Upon reviewing our latest valuation report, HYBE's share price might be too pessimistic.
Taking Advantage
- Click through to start exploring the rest of the 83 Fast Growing KRX Companies With High Insider Ownership now.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A298380
ABL Bio
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
High growth potential with adequate balance sheet.